Patents by Inventor Duc Bui Minh

Duc Bui Minh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10052370
    Abstract: Protein conjugate comprising a protein antigen for generating an immune response against the HER2/neu protein and an immunogenic carrier covalently bonded to said protein antigen, wherein said protein antigen (i) has a sequence segment of 300 or more contiguous amino acids of the amino acid sequence of SEQ ID NO: 1; or (ii) has a variant sequence segment of 300 or more amino acid residues, wherein the amino acid sequence of said variant sequence segment has at least 85% sequence identity to a sequence portion from SEQ ID: 1; or (iii) has a variant sequence segment of 300 or more amino acid residues and has from 1 to 10 substitutions, deletions or additions in said variant sequence segment compared to a sequence segment of 300 or more amino acid residues of the amino acid sequence of SEQ ID NO: 1 or 2.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: August 21, 2018
    Assignees: ICON GENETICS GMBH, UNIVERSITY OF SOUTHAMPTON
    Inventors: Natalia Savelyeva, Franziska Jarczowski, Romy Kandzia, Anja Nickstadt, Frank Thieme, Victor Klimyuk, Yuri Gleba, Duc Bui-Minh, Freda K. Stevenson, Warayut Chotprakaikiat
  • Publication number: 20160015796
    Abstract: Protein conjugate comprising a protein antigen for generating an immune response against the HER2/neu protein and an immunogenic carrier covalently bonded to said protein antigen, wherein said protein antigen (i) has a sequence segment of 300 or more contiguous amino acids of the amino acid sequence of SEQ ID NO: 1; or (ii) has a variant sequence segment of 300 or more amino acid residues, wherein the amino acid sequence of said variant sequence segment has at least 85% sequence identity to a sequence portion from SEQ ID: 1; or (iii) has a variant sequence segment of 300 or more amino acid residues and has from 1 to 10 substitutions, deletions or additions in said variant sequence segment compared to a sequence segment of 300 or more amino acid residues of the amino acid sequence of SEQ ID NO: 1 or 2.
    Type: Application
    Filed: March 11, 2014
    Publication date: January 21, 2016
    Applicants: ICON GENETICS GMBH, UNIVERSITY OF SOUTHAMPTON
    Inventors: Natalia Savelyeva, Franziska Jarczowski, Romy Kandzia, Anja Nickstadt, Frank Thieme, Victor Klimyuk, Yuri Gleba, Duc Bui-Minh, Freda K. Stevenson, Warayut Chotprakaikiat
  • Patent number: 8715688
    Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: providing an antibody preparation, providing at least one expression library, identifying antigens which bind, screening the identified antigens, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 6, 2014
    Assignee: Valneva Austria GmbH
    Inventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitte Tempelmaier, Claire M. Fraser, Steven Gill
  • Publication number: 20130034575
    Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to auto-immunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: providing an antibody preparation, providing at least one expression library, identifying antigens which bind, screening the identified antigens, identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods.
    Type: Application
    Filed: September 13, 2012
    Publication date: February 7, 2013
    Applicant: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitte Tempelmaier, Claire M. Fraser, Steven Gill
  • Patent number: 8323660
    Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:—providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—screening said at least one expression library with said antibody preparation,—identifying antigens which bind in said screening to antibodies in said antibody preparation,—screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: December 4, 2012
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitre Tempelmaier, Claire M. Fraser, Steven Gill
  • Patent number: 7968297
    Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: —providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —screening said at least one expression library with said antibody preparation, —identifying antigens which bind in said screening to antibodies in said antibody preparation, —screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pat
    Type: Grant
    Filed: January 21, 2002
    Date of Patent: June 28, 2011
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitte Tempelmaier, Claire M. Fraser, Steven Gill
  • Publication number: 20110020402
    Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:—providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogren, tumor, allergen or tissue or host prone to auto-immunity,—providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—screening said at least one expression library with said antibody preparation, identifying antigens which bind in said screening to antibodies in said antibody preparation, —screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathog
    Type: Application
    Filed: August 9, 2010
    Publication date: January 27, 2011
    Inventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitre Tempelmaier, Claire M. Fraser, Steven Gill
  • Patent number: 7771728
    Abstract: Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps: —providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity, —screening said at least one expression library with said antibody preparation, —identifying antigens which bind in said screening to antibodies in said antibody preparation, —screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pat
    Type: Grant
    Filed: December 21, 2006
    Date of Patent: August 10, 2010
    Assignee: Intercell AG
    Inventors: Andreas Meinke, Eszter Nagy, Uwe Von Ahsen, Christoph Klade, Tamas Henics, Wolfgang Zauner, Duc Bui Minh, Oresta Vytvytska, Hildegard Etz, Agnieszka Dryla, Thomas Weichhart, Martin Hafner, Brigitte Tempelmaier, Claire M. Fraser, Steven Gill